Last reviewed · How we verify

AAV OPTIRPE65 — Competitive Intelligence Brief

AAV OPTIRPE65 (AAV OPTIRPE65) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gene therapy. Area: Ophthalmology.

phase 2 Gene therapy RPE65 Ophthalmology Biologic Live · refreshed every 30 min

Target snapshot

AAV OPTIRPE65 (AAV OPTIRPE65) — MeiraGTx UK II Ltd. Gene therapy targeting RPE65

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AAV OPTIRPE65 TARGET AAV OPTIRPE65 MeiraGTx UK II Ltd phase 2 Gene therapy RPE65
voretigene neparvovec-rzyl voretigene neparvovec-rzyl Spark Therapeutics, Inc. marketed Gene therapy RPE65 gene
AAV2-hRPE65v2,voretigene neparvovec-rzyl AAV2-hRPE65v2,voretigene neparvovec-rzyl Spark Therapeutics, Inc. phase 3 Gene therapy RPE65 gene
Onasemnogene Abeparvovec-brve Onasemnogene Abeparvovec-brve Novartis Pharmaceuticals marketed Gene Therapy SMN1 gene
p53 with chemotherapy p53 with chemotherapy Shenzhen SiBiono GeneTech Co.,Ltd marketed Gene therapy; recombinant adenovirus vector p53 (tumor suppressor protein)
Onasemnogene Abeparvovec-xioi Onasemnogene Abeparvovec-xioi Novartis Gene Therapies marketed Gene therapy SMN1 gene
rAd-p53 gene rAd-p53 gene Shenzhen SiBiono GeneTech Co.,Ltd marketed Gene therapy; oncolytic virus p53 tumor suppressor gene

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gene therapy class)

  1. Spark Therapeutics, Inc. · 4 drugs in this class
  2. MeiraGTx UK II Ltd · 3 drugs in this class
  3. Novartis Gene Therapies · 2 drugs in this class
  4. Kolon TissueGene, Inc. · 2 drugs in this class
  5. Krystal Biotech, Inc. · 2 drugs in this class
  6. Abeona Therapeutics, Inc · 2 drugs in this class
  7. Larimar Therapeutics, Inc. · 1 drug in this class
  8. 4D Molecular Therapeutics · 1 drug in this class
  9. Medeor Therapeutics, Inc. · 1 drug in this class
  10. MeiraGTx, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AAV OPTIRPE65 — Competitive Intelligence Brief. https://druglandscape.com/ci/aav-optirpe65. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: